睿知中国医院研究地图
候选清单

即将招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 8 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 80 岁;性别:仅女性

    登记记录的入选字段

  2. histologically or cytologically documented HR+/HER2- breast cancer

    入选标准第 4 条

  3. No more than 3 lines of prior systemic therapy for advanced disease

    入选标准第 9 条

    No more than 1 line of chemotherapy or antibody-drug conjugate (ADC) administered in the advanced setting

    入选标准第 10 条

    No prior CDK4/6 inhibitor therapy for advanced disease, or only 1 line of CDK4/6 inhibitor therapy with treatment duration > 6 months

    入选标准第 11 条

    Women of child bearing potential must agree to use a contraceptive method during the treatment period and for at least 180 days after the last dose of experiment treatment

    入选标准第 13 条

    Unresolved Grade ≥2 toxicities (per CTCAE Version 6.0) attributable to any prior therapy, except alopecia

    排除标准第 3 条

  4. ECOG PS of 0-1

    入选标准第 2 条

  5. Other malignancies diagnosed within 5 years, excluding cured non-melanoma skin cancer, cervical carcinoma in situ and papillary thyroid carcinoma

    排除标准第 7 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07745257,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Women aged ≥ 18 years
  2. ECOG PS of 0-1
  3. Life expectancy of at least 12 weeks
  4. histologically or cytologically documented HR+/HER2- breast cancer
  5. radiologically confirmed brain parenchymal metastases without the need for immediate local therapy
  6. measurable brain metastasis lesion according to RANO-BM criteria
  7. Must have active brain metastases, defined as newly diagnosed brain metastases or progressive brain metastases following prior local therapy
  8. Prior systemic therapy must meet all the following criteria:
  9. No more than 3 lines of prior systemic therapy for advanced disease
  10. No more than 1 line of chemotherapy or antibody-drug conjugate (ADC) administered in the advanced setting
  11. No prior CDK4/6 inhibitor therapy for advanced disease, or only 1 line of CDK4/6 inhibitor therapy with treatment duration > 6 months
  12. Adequate hematological, hepatic and renal function
  13. Women of child bearing potential must agree to use a contraceptive method during the treatment period and for at least 180 days after the last dose of experiment treatment
  14. Patients must be able to participate and comply with treatment and follow-up

排除标准:Exclusion Criteria:

  1. Patients with leptomeningeal metastases, brainstem metastases or skull metastases
  2. Prior receipt of anti-angiogenic agents or Culmerciclib
  3. Unresolved Grade ≥2 toxicities (per CTCAE Version 6.0) attributable to any prior therapy, except alopecia
  4. Patients with visceral crisis,defined as severe organ dysfunction assessed by symptoms, signs, laboratory examinations and rapid disease progression
  5. Inability to swallow capsules or tablets
  6. Any severe and/or uncontrolled medical disease
  7. Other malignancies diagnosed within 5 years, excluding cured non-melanoma skin cancer, cervical carcinoma in situ and papillary thyroid carcinoma
  8. Radiographic evidence of tumor invasion of major vessels, or high risk of tumor invasion into major vessels resulting in life-threatening hemorrhage as assessed by the investigator
  9. Patients with arterial or venous thromboembolic events within 6 months, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism
  10. Participation in other anti-tumor clinical trials within 4 weeks prior to enrollment
  11. Any other condition that the investigator considers inappropriate to participate in this trial

引自 ClinicalTrials.gov, NCT07745257, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07745257,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07745257